Micromet Inc.

David F. Hale is one of our co-founders and has served as Executive Chairman of our Board of Directors since December 2007. Mr. Hale served as our Interim CEO from January 2008 to August 2008 and as Non-Executive Chairman of our Board from August 2003 to December 2007. Mr. Hale is Chairman and Chief Executive Officer of Hale BioPharma Ventures. He served as President and Chief Executive Officer and a director of CancerVax Corporation, a biopharmaceutical company, from October 2000 through its merger with Micromet, Inc., in 2006 where he became Chairman. He was President and Chief Executive Officer and a director of Women First HealthCare, Inc., from January 1998 to May 2000. Mr. Hale served as President, Chief Executive Officer, Chairman and a director of Gensia Inc., a biopharmaceutical company which merged to become Gensia Sicor, from May 1987 to November 1997. Prior to joining Gensia, Mr. Hale was President and Chief Executive Officer and a director of Hybritech, Inc., and previously held sales, marketing and general management positions with Johnson & Johnson and Becton Dickinson. Mr. Hale serves as Chairman of the boards of directors of Santarus, Inc., and SkinMedica, Inc., specialty pharmaceutical companies, and Metabasis Therapeutics, Inc., a biopharmaceutical company. He also serves as a director of privately-held biotechnology and specialty pharmaceutical companies including Verus Pharmaceuticals, Inc., and Conatus Pharmaceuticals. Mr. Hale is also a co-founder and member of the boards of directors of industry organizations including BIOCOM/San Diego, the California Healthcare Institute, and CONNECT and is a member of the boards of directors of the Biotechnology Industry Organization and Rady Children’s Hospital, the San Diego Economic Development Corporation, and the Biotechnology Institute. Mr. Hale received a Bachelor of Arts degree in Biology and Chemistry from Jacksonville State University.

Barclay A. Phillips, age 46, has served as our Chief Financial Officer since August 2008. Previously, he served as a member of our board of directors from 2000 until his appointment as our Chief Financial Officer in August 2008. From 1999 to August 2008, Mr. Phillips was a Managing Director of Vector Fund Management. From 1991 to 1999, Mr. Phillips served in various roles including Director of Private Placements and Biotechnology Analyst for INVESCO Funds Group, Inc. From 1985 to 1990, Mr. Phillips held positions in sales and trading with Paine Webber, Inc. and Shearson Lehman Hutton, Inc. Over the last ten years, Mr. Phillips has held board positions for a number of public and private companies and currently serves as a director of Acorda Therapeutics, Inc., a publicly traded biopharmaceutical company. Mr. Phillips received a B.A. in economics from the University of Colorado in Boulder.

Christian Itin, Ph.D., age 44, has served as our Chief Executive Officer and as a director since May 2006, and has served in the following capacities with our subsidiary Micromet AG: Chief Executive Officer from March 2004 to May 2006, Chief Business Officer from 2002 to March 2004, Vice President of Business and Corporate Development from 2001 to 2002, Vice President of Corporate Development from 2000 to 2001 and Head of IP and Licensing from 1999 to 2000. Before joining Micromet, Dr. Itin was a co-founder of Zyomyx, Inc., a protein chip company in Hayward, California. Dr. Itin received a Diploma in biology and a Ph.D. in cell biology from the University of Basel, Switzerland. In addition, he also performed post-doctoral research at the Biocenter of Basel University and at the Stanford University School of Medicine.

Carsten Reinhardt, M.D., Ph.D., age 42, has served as our Chief Medical Officer since June 2007 From May 2006 to June 2007, he served as our Senior Vice President, Clinical Development, and in the same capacity at our subsidiary Micromet AG since June 2005. Before joining Micromet, Dr. Reinhardt was International Medical Leader for Herceptin at Hoffmann-La Roche (Basel, Switzerland) between 2003 and 2005, and Head of Clinical Development at Fresenius Biotech (Munich, Germany) from 2000 to 2003. From 1995 to 2000, Dr. Reinhardt worked at various academic institutions (University of Tübingen, Max-Planck-Institute of Psychiatry, Munich) to complete his curriculum in Neurology. Between 1991 and 1995, Dr. Reinhardt performed his Ph.D. thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany. Dr. Reinhardt received a Medical Degree in 1994 from University of Munich, Germany. Dr. Reinhardt is a Visiting Professor for Pharmaceutical Medicine at the University of Basel.

Mark Reisenauer, age 43, has served as our Chief Commercial Officer since September 2007. He joined Micromet from Abbott, where he was the General Manager of the Oncology Franchise from 2002 to 2006 and most recently Divisional Vice President and General Manager of the Neuroscience franchise from 2006 to September 2007. Before joining Abbott, Mr. Reisenauer was the Director of Marketing for Breast Cancer (Portfolio Lead) and the Director of Breast Cancer Products at Pharmacia from 1999 to 2002. From 1997 to 1999 he was the Associate Director of Oncology Global Marketing at Bristol-Myers Squibb and from 1988 to 1997 held various positions in sales and oncology marketing at Zeneca. Mr. Reisenauer holds a B.A. degree in Political Science from the University of Wisconsin.

Patrick A. Baeuerle, Ph.D., age 51, has served as our Chief Scientific Officer since May 2006, and has served as Chief Scientific Officer of Micromet AG since 1998. From 1996 to 1998, Dr. Baeuerle headed the drug discovery activities of Tularik Inc. in South San Francisco, CA, as Director, Drug Discovery. From 1994 to 1996, Dr. Baeuerle served as a full Professor and Chairman of Biochemistry at the Medical Faculty of Freiburg University, Germany. In 1989, he was awarded a group leader position at the Gene Center in Martinsried, Germany, where he did seminal research on transcription factor NF-kappaB. According to a survey by the institute for Scientific Information (ISI, Philadelphia, PA, USA), Dr. Baeuerle was Germany’s most frequently cited biomedical scientist of the past decade, and 38th worldwide. He has published more than 220 scientific papers. In addition, Dr. Baeuerle is the first recipient of the Prix Européen de l’Avenir and an elected member of the European Molecular Biology Organization (EMBO). He was appointed Honorary Professor of Immunology at the University of Munich in 2000. Dr. Baeuerle performed his Ph.D. work at the Max Planck Institute for Psychiatry in Martinsried and at the European Molecular Biology Laboratory (EMBL) in Heidelberg, obtained a Ph.D. degree in biology from the University of Munich, and performed his post-doctoral research with David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology (MIT), Cambridge, MA.

Matthias Alder, lic. iur., LL.M., age 44, has served as our Senior Vice President, General Counsel and Secretary since July 2006. Previously, he was a partner with Cooley Godward LLP, a U.S. law firm, where he established and co-chaired the firm’s East Coast Life Sciences Practice. Starting in 1994 and before joining Cooley in 1997, he was in-house counsel for the pharmaceutical business of Novartis in Basel, Switzerland. Between 1988 and 1994, he worked in law firms in Switzerland and in Miami, FL. He is admitted to practice in California, New York, and Virginia, and the Canton of Zurich, Switzerland. Mr. Alder received an LL.M. degree in International and Comparative Law from the University of Miami in 1990. He earned the equivalent of a J.D. degree (lic. iur.) from the University of Basel, Switzerland, graduating magna cum laude in 1988.

Jens Hennecke, Ph.D., age 41, has served as our Senior Vice President Business Development since March 2009. Previously, he served as our Vice President Business Development from May 2006 to March 2009, and in the same capacity at our subsidiary Micromet AG from 2004 to May 2006. He joined Micromet AG in 2001 and performed various business development functions until his promotion to Vice President in 2004. Dr. Hennecke studied biology at the University of Göttingen, Germany, and performed his Ph.D. thesis at the Institute of Molecular Biology and Biophysics at the ETH Zürich, Switzerland, for which he was awarded the Silver Medal of the ETH. He also performed post-doctoral research in x-ray crystallography with Don Wiley at the Department of Molecular and Cellular Biology of Harvard University.

Erich Felber joined Vienna-based Biovertis AG as its Chief Executive Officer in September 2004. Previously, he was CEO of Munich-based Micromet AG, which he ran from its inception until March 2004. Erich Felber received an MD from Munich University and was group leader of the laboratory for clinical immunology at the University's Institute for Immunology. Subsequently, he moved to Schering-Plough as a project leader in clinical research, then gained an MBA from INSEAD (Fontainebleau, France) and was finally manager with Andersen Consulting's strategic services group before co-founding Micromet in 1993.

Dr. Kapil Dhingra, age 49, has served as a member of our Board of Directors since February, 2009. Dr. Dhingra is the sole member of KAPital Consulting, LLC, a consulting company dedicated to assisting biotechnology, pharmaceutical and diagnostic companies realize clinical and commercial advances in oncology, since June 2008. From 1999 to June 2008, Dr. Dhingra worked in positions of increasing responsibility at Hoffman-La Roche, most recently serving as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to Hoffmann-La Roche, from 1996 to 1999, Dr. Dhingra worked as a Clinical and Senior Clinical Research Physician with Eli Lilly and Company. and from 1989 to 1996, a Clinical Instructor, Assistant Professor of Medicine ( tenure-track) at the University of Texas M.D. Anderson Cancer Center. Throughout his industry career, he maintained an active faculty appointment, initially at Indiana University School of Medicine from 1997 to 1999 as Clinical Associate Professor, and, more recently, at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Dr. Dhingra holds an M.B., B.S. degree (equivalent to a US M.D. degree) from the All India Institute of Medical Services, and has performed postgraduate work the All India Institute of Medical Services, the Lincoln Medical and Mental Health Center (New York Medical College), Bronx, NY and Emory University School of Medicine, Atlanta, GA.

Dr. Schoettler served as Colorado's Lt. Governor from 1995 to 1999. In 1997, she co-chaired the successful G-8 Summit of world leaders held in Denver, Colorado. She negotiated solutions to some of Colorado's toughest environmental problems and led a highly successful educational reform. From 1987 to 1995, Dr. Schoettler served two terms as Colorado State Treasurer and as a trustee of the Public Employees Retirement Association, the state's $24 billion pension fund. She was elected to two terms on the Douglas County Board of Education, serving four years as president, and was a trustee of the University of Northern Colorado. Currently, she sits on four non-profit boards, the Center for Women's Health Research at the University of Colorado, ProgressNow, Colorado Conservation Trust, and Gunnison Ranchland Conservation Legacy. Dr. Schoettler received her BA degree with honors in economics from Stanford University and her MA and PhD degrees in history from the University of California at Santa Barbara. She has founded two banks and continues to help run the California cattle ranch where she was raised and to manage several real estate partnerships. Among her many awards is the French Legion of Honor, France's highest civilian award, presented to her by French President Jacques Chirac. Ambassador Schoettler is married to Dr. Donald Stevens, Managing Director of the Institute for International Business at the University of Colorado at Denver. Together they have five children and live in Parker, Colorado. She recently conquered her great fear of heights and finished climbing all 56 of Colorado's 14,000 foot high peaks.

Jeffrey V. Ravetch is a Theresa and Eugene M. Lang Professor at Rockefeller University. He is a member of National Academy of Sciences and received numerous awards for his groundbreaking research in immunology. He is a leading expert on antibody-mediated effector mechanisms and immune regulation.

Michael J. Keating is Professor of Medicine and internist for the Department of Hematology at University Texas, MD Anderson Cancer Center. His awards include the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research and the 1996 'Best Doctor of America Leukemia Award.' Dr. Keating is a leading expert on chronic lymphocytic leukemia (CLL).

Otello Stampacchia, Ph.D., age 39, has served as a member of our board of directors since May 2006, and was a member of the supervisory board of our subsidiary Micromet AG until May 2006. Dr. Stampacchia has been an Adviser to Omega Fund since 2005. The Omega Fund acquires ownership interests in public and private biopharmaceutical and device companies, focusing on Western Europe and the United States. Dr. Stampacchia has been involved in various advisory activities in biotechnology since 2001. Previously, Dr. Stampacchia was a member of the health care Corporate Finance and M&A team at Goldman Sachs International in London, and he also helped initiate the health care investment activities of Index Securities (now Index Ventures). Dr. Stampacchia has a Ph.D. in Molecular Biology from the University of Geneva (Switzerland), a European Doctorate in Biotechnology (EDBT) from the European Association for Higher Education in Biotechnology, and a M.Sc. in Genetics from the University of Pavia (Italy).

Dr. Peter Johann is a Managing General Partner of NGN Capital. He joined from Boehringer Ingelheim where he was the Division Head of Corporate Development. Dr. Johann has established a worldwide network in the Biotech and Pharmaceutical Industry. His responsibilities at Boehringer Ingelheim included strategic planning, strategic projects, M&A, business development and licensing. He identified and evaluated several licensing, M&A and co-promotion deals. Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim where he was Head of Business Development and Marketing Molecular Medicine. Besides marketing activities Dr. Johann was involved in setting up and managing joint venture companies as member of the supervisory board. He was also responsible for licensing activities in this field. Prior to that position he had Marketing, Sales and Business Development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of Biopharmaceuticals. Dr. Johann has additional industry experience in Business Development and Marketing of pharmaceutical products with Kaneka in Japan and with Rohm in Germany in industrial enzymes. Dr. Johann obtained his Ph.D. from the Technical University Munich. He currently serves on the Board of Directors of Micromet, Inc. (Nasdaq: MITI) and Nitec Pharma AG. He previously served on the Board of Directors of Jerini AG (FWB: J14) and as an observer on the board of Santhera Pharmaceuticals AG.

Richard A. Flavell is a Sterling Professor and Chairman of Immunobiology at Yale School of Medicine, and investigator at the Howard Hughes Medical Institute. He was previously chief scientific officer at Biogen Corporation, and is member of both the Royal Society and National Academy of Sciences. He is a leading expert on activation and differentiation of T cells.

Ronald Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine, Chief of the Division of Oncology, at Stanford University School of Medicine. Highly regarded for his achievements in the therapy of B cell malignancies, Dr. Levy pioneered the clinical development of the anti-CD20 monoclonal antibody rituximab (Rituxan(R)).